AstraZeneca – Oxford Cancer Symposium (AZOCS), Thursday 13th September 2018 | Keble College, Oxford


AstraZeneca – Oxford Cancer Symposium (AZOCS)

Thursday 13th September 2018 | Keble College, Oxford


On Thursday 13th June, Keble College in Oxford hosted the
inaugural AstraZeneca – Oxford Cancer Symposium (AZOCS).


Over 125 researchers from Oxford and 90 cancer scientists from AstraZeneca and MedImmune attended to develop and establish a series of collaborative cancer research projects.


Almost 100 posters and 27 presentations showcased current
projects across all organisations, covering DNA Damage
, Early-Phase Clinical Trials, Enabling Technologies,
Epigenetics, Immuno-Oncology, and Radiation Oncology.



David Andrews from AstraZeneca in Cambridge commented:

“The feedback I have had from AstraZeneca and Medimmune colleagues has been overwhelmingly positive and it is clear there are many opportunities for us to collaborate – from target identification and validation all the way through to patient studies. We are very excited by the prospect of deploying our disease know-how, target knowledge and
portfolio of drugs in development alongside Oxford’s excellent
access to patients and patient-derived models.
Oxford’s specific disease and biological knowledge should also
enable us to more deeply understand biological targets

and bring benefit to patients.”


Chris Schofield from the Department of Chemistry in Oxford
emphasised: “The AZ-Oxford meeting showcased brilliant
science from both organisations aimed at enabling breakthrough treatments for cancer. The truly impressive research ranged from fundamental work on the origins of tumorigenesis to clinical studies. There is clearly enormous potential for industry and academic to work synergistically to cement the UK’s leading position in cancer research.”



Poster winners for the AZOCS Poster Prizes 2018 are:


A Fluorescent Reporter of Base Editing

Activity Reveals Editing Characteristics of APOBEC3A

– Matthew Coelho, AstraZeneca

A gene signature associated with PTEN activation defines good outcomes in intermediate-risk prostate cancer cases

– Chee Wee Ong, University of Oxford



If you attended the Symposium and would like to find out any more information about any of the presentations you saw, any of the posters, or further information on the CRUK Oxford Centre or AstraZeneca/MedImmune then please contact .


If you would like further information on how to download the Networking Meeting App ATTENDIFY, please contact .